Use of COMT inhibitors as analgesics

Details Use of COMT inhibitors as analgesics Use of COMT inhibitors as analgesics

2002-09-13

2004-04-20

Kim, Vickie (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

C-o-group doai

Reexamination Certificate

active

06723754

ABSTRACT:

This application is a national stage filing of PTC international Application No. PCT/FI01/00265, filed on Mar. 16, 2001. This application also claims the benefit of priority under 35 U.S.C. §119(a) to Finnish patent application no. 20000635, filed on Mar. 17, 2000.
FIELD OF THE INVENTION
The invention relates to the use of catechol-O-methyl transferase (COMT) inhibitors in the treatment or control of pain in mammals.
BRIEF DESCRIPTION OF THE PRIOR ART
Analgesic drugs can be divided into three groups: the nonopioid analgesics, the opioid analgesics and the adjuvant analgesics. The nonopioid analgesics such as aspirin, paracetamol and the nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin and ibuprofen, act peripherally and in some cases also centrally through inhibition of various enzymes, mainly cyclooxygenase. The inhibition of cyclooxygenase leads to reduction in the hyperalgesic prostaglandins. The opioid analgesics produce analgesia through binding to the opiate receptors in the central nervous system. Adjuvant analgesics increase the analgesic effects of the opioids or act as analgesics themselves. This group of drugs include miscellaneous drugs e.g. anticonvulsants like carbamazepine, tricyclic antidepressants, steroids etc.
Inhibitors of catechol-O-methyl transferase (COMT) as well as methods for the preparation thereof are known in the prior art, e.g. in GB-A-2 200 109, EP-A-237 929 and WO-A-96 37456 as well as i.a. in British Journal of Pharmacology, vol.126, 1999, p.1667-1673 (E. Rivas et al.), in Journal of Medical Chemistry, vol.35(24), 1992, p.4584-4588 (R. A. Pérez et al.) and in Biochemical Pharmacology, vol.45(10), 1993, p.1973-1981 (R. A. Pérez et al.).
COMT is an enzyme which metabolises i.a. endogenous sympathomimetic catecholamines like dopamine and noradrenaline. COMT enzyme metabolises also exogenously adminstered catecholamines, e.g. levodopa. The inhibitors of COMT have been used i.a. in the treatment of Parkinson's disease for inhibiting the metabolism of levodopa. As specific examples i.a. entacapone ((E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide) and tolcapone (3,4-dihydroxy-4′-methyl-5-nitrobenzophenone) can be mentioned.
Furthermore, WO-A-98 27973 describes the use of the COMT inhibitors, especially nitecapone (3-(3,4-dihydroxy-5-nitrophenyl)methylene-2,4-pentanedione), in the prevention of diabetic vascular dysfunctions. Nitecapone is also known to have a natriuretic effect (Eklöf et al. J. Am. Soc. Nephrology 5 (3), 657, 1994, Holtbäck et al., J. Am. Soc. Nephrology, 7(9), 1633, 1996).
U.S. Pat. No. 5,489,614 discloses catechol derivatives useful as antioxidants in the prevention or treatment of tissue damage induced by lipid peroxidation.
SUMMARY OF THE INVENTION
The object of the invention is to provide further use of the COMT inhibitors, i.e. the use of COMT inhibitors in the treatment or control of pain in mammals, including animals and human beings.


REFERENCES:
patent: 5112861 (1992-05-01), Bäckstrom et al.
patent: 5236952 (1993-08-01), Bernauer et al.
patent: 5283352 (1994-02-01), Backstrom et al.
patent: 5389653 (1995-02-01), Bernauer et al.
patent: 5446194 (1995-08-01), Bäckstrom et al.
patent: 5470737 (1995-11-01), Weinshilboum et al.
patent: 5489614 (1996-02-01), Korkolainen et al.
patent: 6169103 (2001-01-01), Purchase, Jr. et al.
patent: 6599530 (2003-07-01), Vahervuo
patent: 898879 (1962-06-01), None
patent: WO 96/37456 (1996-11-01), None
patent: WO 98/27973 (1998-07-01), None
Walpole et al., “Analogues of Capsaicin with Agonist Activity as Novel Analgesic Agents; Structure-Activity Studies. 1. The Aromatic ‘A-Region’,” J. Med. Chem. vol. 36, pp. 2362-2372 (1993).
English abstract of Masatoshi et al., JP7215952 A 19950815, with attached first page of JP 7-215952.
Pertovaara et al., “Pain Behavior and Response Properties of Spinal Dorsal Horn Neurons Following Experimental Diabetic Neuropathy in the Rat: Modulation by Nitecapone, a COMT Inhibitor with Antioxidant Properties,” Experimental Neurology, vol. 167, pp. 425-434 (2001).
S. H. Ferreira et al., “Bradykinin Initiates Cytokine-Mediated Inflammatory Hyperalgesia”, Br. J. Pharmacol., vol. 110, pp. 1227-1231 (1993).
F. Q. Cunha et al., “Pharmacological Modulation Of Secondary Mediator Systems—Cyclic AMP And Cyclic GMP—On Inflammatory Hyperalgesia”, British Journal of Pharmacology, vol. 127, pp. 671-678 (1999).
P. A. Aho et al., “Role Of Gastric Mucosal Eicosanoid Production In The Cytoprotection Induced By Nitecapone”, Scand. J. Gastroenterol, vol. 27, pp. 134-138 (1992).
C. J. Sih et al., “Mechanism of Prostaglandin Biosynthesis”, Journal of the American Chemical Society, vol. 92, p. 6670 (1970).
D. W. Busija et al., “Eicosanoid Synthesis Elicited By Norepinephrine In Piglet Parietal Cortex”, Brain Research, vol. 403, pp. 243-248 (1987).
L. O. Randall et al., “A Method For Measurement Of Analgesic Activity On Inflamed Tissue”, Arch. Int. Pharmacodyn., vol. 111, pp. 409-419 (1957).
K. Gyires et al., “The Use Of The Writhing Test In Mice For Screening Different Types Of Analgesics”, Arch. Int. Pharmacodyn., vol. 267, pp. 131-140 (1984).
N. B. Eddy et al., “Synthetic Analgesics”, J. Pharmacol. Ther., vol. 98, pp. 121-137 (1950).
E. Rivas et al., “In Vivo Effects Of New Inhibitors Of Catechol-O-Methyl Transferase”. British Journal of Pharmacology, vol. 126, pp. 1667-1673 (1999).
R. A. Pérez et al., “Dihydroxynitrobenzaldehydes And Hydroxymethoxynitrobenzaldehydes: Synthesis And Biological Activity as Catechol-O-Methyltransferase Inhibitors”, J. Med. Chem., vol. 35, pp. 4584-4588 (1992).
R. A. Pérez et al., “Inhibition Of Catechol-O-Methyltransferase By 1-Vinyl Derivatives Of Nitrocatechols And Nitroguaiacols”, Biochemical Pharmacology, vol. 45, No. 10, pp. 1973-1981 (1993).
A. C. Eclöf et al., “Natriuretic And Vasodilating Effects of Dopamine Are Mimicked By Oral Administration of a Catechol-O-Methyltransferase (COMP) Inhibitor”, J. Am. Soc. Nephrology, vol. 5, paragraph 23P, p. 657 (1994).
U. Holtbäck et al., “Regulators of Renal Dopamine Metabolism Control Salt Excretion”, .J. Am. Soc. Nephrology, vol. 7, Paragraph A1922, p. 1633 (1996).
K. L. Green, “The Anti-Inflammatory Effect of Catecholamines In The Peritoneal Cavity And Hind Paw Of The Mouse”, Br. J. Pharmac., vol. 45, pp. 322-332 (1972).
S. K. Bhattacharya et al., “Central Catecholaminergic Modulation Of Carrageenin-Induced Pedal Oedema in Rats”, Res Exp Med, vol. 186, pp. 365-374 (1986).
M. Nakamura et al., “A Peripheral Sympathetic Component In Inflammatory Hyperalgesia”, European Journal of Pharmacology, vol. 135, pp. 145-153 (1987).

Affiliated with

Also associated with

Rating

Use of COMT inhibitors as analgesics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of COMT inhibitors as analgesics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of COMT inhibitors as analgesics will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3247040